Marketplace

Home / Marketplace

 

Marketplace

Breakthrough Autism Diagnostic Technology Provides High
Degree of Diagnostic Accuracy for Autism.

With an estimated 3.5 million Americans living with Autism Spectrum Disorder (ASD), the Center for Disease Control recommends all children be screened for developmental delays and disabilities at 18 and 24 month well baby visits. The recommendation specifically indicates screening for ASD. It is anticipated as many as 4 million Americans will suffer with ASD within the next 10 years. Currently diagnosing ASD requires a team of specialists observing the individual over a period of time, which involves time and money.

As the only patented diagnostic system of its kind, this breakthrough technology provides healthcare workers and parents a 94%+ accuracy diagnosis of ASD as early as 5-months old. The technology can be integrated with any MRI scan equipment to perform automated diagnoses using scans from existing systems. Sold as software and turnkey system, the technology will perform the diagnostics.

This new technology will diagnose a child with ASD as young as five months old with greater than 94% accuracy. The technology has proven equally accurate diagnosing dyslexia, as well. Further, the technology can be used to diagnose Alzheimer’s Disease with >90% accuracy. The high accuracy provides physicians, patients and caregivers a sense of security that a diagnosis is correct. With such degenerative disorders as Alzheimer’s Disease, the patient’s brain can be monitored with repeated scans. The technology can be expanded for use with other brain disorders and diseases.

The global ASD market was valued at $346.2 million in 2013 and $360.9 million in 2014. This market is expected to grow to $412.7 million by 2019, a compound annual growth rate (CAGR) of 2.7%. ASD is reported to occur in all racial, ethnic, and socioeconomic groups. ASD is about 4.5 times more common among boys (1 in 42) than among girls (1 in 189). Studies in Asia, Europe, and North America have identified individuals with ASD with an average prevalence of between 1% and 2%.